News

October 6, 2026

Applied Biologics Announces Manufacturing Milestone in APPB-515 Osteoarthritis Gene Therapy Program

September 30, 2026

Applied Biologics Publishes New Translational Research Demonstrating Ligament Regeneration with XWRAP®-Based Biologic Augmentation

September 24, 2026

Applied Biologics Announces Publication of New XWRAP® Translational Research Demonstrating More Favorable Wound-Healing Biology

September 22, 2026

Applied Biologics Announces Last Patient, Last Visit in CAMPX Randomized Controlled Trial of XWRAP®

September 17, 2026

Applied Biologics Receives Service-Disabled Veteran-Owned Small Business Certification

September 15, 2026

Applied Biologics Launches APPB-429 Gene Therapy Program for Diabetic Peripheral Neuropathy

September 8, 2026

Applied Biologics Welcomes New CMS RAPID Pathway and Expanded CMS-FDA Coordination for Innovative Medical Technologies

September 3, 2026

Applied Biologics Achieves Key Preclinical Milestone in Disease-Modifying Osteoarthritis Gene Therapy Program

September 1, 2026

Applied Biologics Activates First Clinical Site in Phase 3 BIOxHEAL™ Trial

August 25, 2026

Applied Biologics Announces Acceptance of Updated CAMPX XWRAP® Clinical Trial Results for Presentation at SAWC Fall 2026

August 24, 2026

Applied Biologics CEO and Former Marine F/A-18 Pilot Edward Britt Selected as Honorary Commander at Luke Air Force Base

August 19, 2026

Applied Biologics Welcomes CMS’ Continued Commitment to Clinical Evidence in Advanced Wound Care

August 18, 2026

Applied Biologics Announces Acceptance of XWRAP® Translational Research for Presentation at SAWC Fall 2026

August 12, 2026

Applied Biologics Launches National Health System Partnership Initiative

August 10, 2026

CMS Proposed 2027 Medicare Policy Continues Recognition of the FDA’s Section 351 Biologic Pathway

August 5, 2026

Applied Biologics Receives Central IRB Approval for Phase 3 BIOxHEAL™ Clinical Trial

August 4, 2026

Applied Biologics Marks 10 Years of Continuous AATB Accreditation While Initiating Reaccreditation Process

July 30, 2026

Applied Biologics Announces Successful GMP Manufacturing of Initial Clinical Lots of BIOxHEAL™

July 28, 2026

Applied Biologics Expands National Commercial Payer Engagement Strategy for XWRAP®

July 27, 2026

Applied Biologics Announces Extension of Longstanding System-Wide Agreement With Providence Health & Services for XWRAP®

July 21, 2026

Applied Biologics Initiates Multi-Center Real-World Outcomes Study of XWRAP® Across Chronic Wound Types

July 20, 2026

Applied Biologics Announces Submission of XWRAP® Translational Research Abstract for Consideration at SAWC Fall 2026

July 14, 2026

Applied Biologics Announces Successful Manufacture of First Research Construct for Disease-Modifying Osteoarthritis Gene Therapy Program

July 9, 2026

Applied Biologics Introduces ECM Preservation Technology™ as the Proprietary Manufacturing Platform Behind XWRAP®

July 7, 2026

Applied Biologics Announces VA Federal Supply Schedule Contract Modification Supporting Long-Term Access to XWRAP®

July 1, 2026

Applied Biologics Announces Expanded Strategic Focus on Surgical Applications of XWRAP®

June 30, 2026

Applied Biologics Announces National Commercial Expansion to Support Continued Growth of XWRAP® and Future Biologic Product Pipeline

June 24, 2026

Applied Biologics Announces Completion of Translational Research Supporting the Biologic Performance of XWRAP®

June 23, 2026

Applied Biologics Announces Submission of Abstract of Single-Layer Amniotic Membrane Plus Standard of Care for Chronic Diabetic Foot Ulcers: An Updated Analysis of The Campx Trial to SAWC Fall 2026

June 17, 2026

Applied Biologics Announces Completion of Planned Enrollment Activities in the CAMPX Randomized Controlled Trial Evaluating XWRAP®

June 15, 2026

Applied Biologics Reports Statistically Significant Improvement in Wound Closure Outcomes in Updated Analyses of the CAMPX Randomized Controlled Trial Evaluating XWRAP®

June 11, 2026

Applied Biologics Launches Preclinical Development Program Focused on Osteoarthritis and Other Degenerative Diseases

June 10, 2026

Applied Biologics Presents Interim CAMPX Clinical Trial Data at the Symposium on Advanced Wound Care (SAWC) Spring 2026

June 9, 2026

Applied Biologics Receives FDA Clearance to Advance BIOxHEAL Into Phase 3 Clinical Development for Diabetic Foot Ulcers